Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study.

Mikayel Narimanyan, Kristina Jamalyan, Anna Balyan, Anders Barth, Staffan Palm et al.

Other Journal of traditional and complementary medicine 2021 9 citations

<\/script>\n

`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'pmid\u003D34765519'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Study Design

Study Type: Other
Sample Size: 179
Population: None

Intervention: Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study. 60 mg
Comparator: placebo
Primary Outcome: None
Effect Direction: Positive
Risk of Bias: Unclear

Abstract

BACKGROUND AND AIM: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, called Kan Jang®, are traditionally used for relieving symptoms of upper-respiratory tract infections (URTIs). This study aimed to assess the efficacy of early intervention with Kan Jang® on the relief and duration of inflammatory symptoms during the acute phase of the disease. EXPERIMENTAL PROCEDURE: A total of 179 patients with URTI symptoms received six Kan Jang® (daily dose of andrographolides: 60 mg) or placebo capsules a day for five consecutive days in this randomized, quadruple-blinded, placebo-controlled, two-parallel-group phase II study. The primary efficacy outcomes were the decrease in the acute-phase duration and the mean URTI symptoms score (sore throat, runny nose, nasal congestion, hoarseness, cough, headache, and fatigue). RESULTS: Early intervention with Kan Jang® significantly increased the recovery rate and reduced the number of sick leave days by >21% (0.64/day) relative to that observed in the placebo group (2.38 vs. 3.02 days, p = 0.0053). Kan Jang® significantly alleviated all URTI symptoms starting from the second day of treatment. A superior anti-inflammatory effect of Kan Jang® to that of placebo was also observed on the white blood cell count (p = 0.007) and erythrocyte sedimentation rate (p = 0.0258). Treatment with Kan Jang® was tolerated well. CONCLUSION: This study demonstrates that early intervention with Kan Jang® capsules reduces the recovery duration of patients by 21% and significantly relieves the severity of typical URTI symptoms.

TL;DR

It is demonstrated that early intervention with Kan Jang® capsules reduces the recovery duration of patients by 21% and significantly relieves the severity of typical URTI symptoms.

Full Text

Name of the medicinal product

KanJang Andrographis® with fixed combination of Andrographis paniculata herb extract and Eleutherococcus senticosus root extract.

Pharmaceutical form

Capsules

Indication for use

Herbal Medicinal Product for the “reduction in the severity and duration of symptoms of uncomplicated respiratory tract infections (common cold)”.

Dosage The recommended daily dose is 2 capsules 3 times per day for adults.

Quantitative Composition

Substance Quantity per one capsule, mg

Active ingredients Herba Andrographidis standardised extract containing 66-110 mg of native dry extract ( DER 4,5-8,0 :1, extraction agent - ethanol* 70 %, V/V) corresponding to 10 mg of the sum of andrographolisdes (andrographolide and deoxydidehydro-andrographolide) and 45-67% of maltodextrin**(adjuvant for adjustment)

250

Radix Eleutherococci root extract, containing 11.4 mg of native dry extract (DER 17-30:1, extraction agent – ethanol 70%, V/V) , corresponding to 194-342 mg of herbal substance (Radix Eleutheorcocci, standardized for the content of eleutherosides B and E (0.4 mg/capsule) and 50% of maltodextrine** (adjuvant for adjustment )

22,8

Inactive ingredients Microcrystalline cellulose Magnesium stearate Vegetable capsule

70 7.2 75

Total weight 425 ± 21

Product: Kan Jang Andrographis Product category: Herbal medicinal product Dosage form: capsules

Daily dose: 6 capsules size 1 Batch number: 50145 Batch size: 5000 capsules

Composition

Product: Placebo Product category: Herbal medicinal product Dosage form: capsules Daily dose: 6 capsules size 1 Batch number: 50137-1 Batch size: 4000 capsules

Composition

PDF

Loading PDF...

Figures

Figure 1

Experimental results examining early intervention with Kan Jang® to treat upper, with data points illustrating key findings related to BACKGROUND AND AIM: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, .

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study.

Embed This Widget

Study Design

Abstract

TL;DR

Full Text

Pharmaceutical form

Herbal Medicinal Product for the “reduction in the severity and duration of symptoms of uncomplicated respiratory tract infections (common cold)”.

Substance Quantity per one capsule, mg

Total weight 425 ± 21

Composition

Composition

Figures

Tables

Used In Evidence Reviews

Similar Papers

Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy.

Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations.

Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis.

Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials.

A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory tract infection.

A review for the neuroprotective effects of andrographolide in the central nervous system.